On this page
GNRHR
gonadotropin releasing hormone receptor
GNRHR is located on the long (q) arm of chromosome 4, at band 4q13.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 4 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The GNRHR gene encodes a specialised receptor protein that sits on the surface of pituitary cells and responds to gonadotropin-releasing hormone (GnRH) from the hypothalamus. When GnRH binds to this receptor, it triggers a cascade of cellular events that ultimately control the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). These hormones are essential for the development of sexual characteristics during puberty and for maintaining fertility throughout adult life.
Variants that impair GNRHR function can prevent normal communication between the hypothalamus and pituitary gland, resulting in insufficient production of LH and FSH. This disruption typically manifests as hypogonadotropic hypogonadism, a condition characterised by delayed puberty, incomplete sexual development, and impaired fertility. The gene is of clinical importance because early diagnosis can enable hormone replacement strategies that support normal physical development and reproductive health.
What the gene does
The GNRHR protein is a member of the G protein-coupled receptor superfamily, which represents one of the largest classes of signalling receptors in human cells. This receptor is embedded in the cell membrane of gonadotroph cells within the anterior pituitary gland, where it serves as the primary sensor for GnRH pulses arriving from the hypothalamus.
When GnRH molecules bind to the receptor's external-facing regions, the protein undergoes a conformational change that activates associated G proteins on the inner surface of the cell membrane. This activation initiates multiple intracellular signalling pathways, including the phospholipase C pathway, which increases calcium levels within the cell and activates protein kinase C. These signalling events ultimately stimulate the synthesis and secretion of LH and FSH, which then travel through the bloodstream to the gonads to regulate sex hormone production and gamete development.
The receptor's activity is finely tuned by the pulsatile pattern of GnRH release from the hypothalamus. Continuous exposure to GnRH typically leads to receptor desensitisation, whilst intermittent pulses maintain responsiveness. This temporal regulation is crucial for normal reproductive physiology, as different pulse frequencies can preferentially favour LH or FSH secretion depending on the physiological context.
Video: Genetics 101
Chromosome location
GNRHR is located on the long arm of chromosome 4 at position 13.2 (4q13.2). The gene spans approximately 19 kilobases of genomic DNA and is organised into three exons. The coding sequence is relatively compact compared to many human genes, reflecting the modest size of the encoded receptor protein. This chromosomal region does not contain particularly high densities of other hormone-related genes, though the genomic neighbourhood includes several genes involved in cellular signalling and metabolic regulation.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The GNRHR protein comprises 328 amino acids arranged in the characteristic topology of G protein-coupled receptors, featuring seven transmembrane helical segments that span the cell membrane. These transmembrane regions are connected by alternating extracellular and intracellular loops, with the N-terminus extending into the extracellular space and the C-terminus residing in the cell's interior. The extracellular loops and N-terminal region form the binding pocket that recognises and captures GnRH, whilst the intracellular regions interact with G proteins to propagate the signal inward. Unlike many related receptors, GNRHR has a relatively short C-terminal tail, which influences its trafficking and regulation within cells.
Key variants
Pathogenic variants in GNRHR are typically inherited in an autosomal recessive pattern, meaning that individuals require changes in both gene copies to develop hypogonadotropic hypogonadism. Most disease-causing variants are missense changes that alter single amino acids within the receptor protein, disrupting either GnRH binding or the receptor's ability to activate downstream signalling pathways. Some variants affect protein folding and trafficking, preventing the receptor from reaching the cell surface where it normally functions. The spectrum of variants shows considerable genetic heterogeneity, with different populations carrying distinct founder mutations that have become more common due to historical population patterns.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.112C>T | p.Arg38Ter | Pathogenic | ★★☆☆ | GNRHR-related disorders |
c.350T>G | p.Leu117Arg | Pathogenic/Likely pathogenic | ★★☆☆ | Hypogonadotropic hypogonadism 7 with or without anosmia |
c.351_352del | p.Ser118fs | Pathogenic/Likely pathogenic | ★★☆☆ | Isolated congenital hypogonadotropic hypogonadism |
c.401T>G | p.Val134Gly | Pathogenic | ★★☆☆ | Hypogonadotropic hypogonadism 7 with or without anosmia |
c.742+2T>C | - | Pathogenic/Likely pathogenic | ★★☆☆ | Hypogonadotropic hypogonadism |
c.784C>T | p.Arg262Trp | Pathogenic/Likely pathogenic | ★★☆☆ | Hypogonadotropic hypogonadism 7 with or without anosmia |
c.797T>G | p.Leu266Arg | Pathogenic/Likely pathogenic | ★★☆☆ | GNRHR-related disorders |
c.836G>A | p.Cys279Tyr | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.847T>C | p.Tyr283His | Pathogenic/Likely pathogenic | ★★☆☆ | Hypogonadotropic hypogonadism 7 with or without anosmia |
c.918CTT[2] | p.Phe309del | Pathogenic/Likely pathogenic | ★★☆☆ | GNRHR-related disorders |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
The principal condition associated with GNRHR variants is isolated hypogonadotropic hypogonadism (GNRHR), an autosomal recessive disorder characterised by insufficient production of sex hormones due to impaired pituitary signalling. Affected individuals typically present during adolescence with delayed or absent puberty, though the condition may not be recognised until adulthood when fertility concerns arise. Clinical features include lack of secondary sexual characteristics, small testes or absent menstrual periods, reduced bone density, and infertility. The term "isolated" indicates that the hypogonadism occurs without other pituitary hormone deficiencies, distinguishing it from broader pituitary disorders. Hormone replacement therapy can often restore normal sexual development and bone health, though fertility may require specialised reproductive interventions.
UK clinical status
GNRHR is included on multiple NHS Genomic Medicine Service panels that guide testing for individuals with reproductive hormone disorders. The gene holds green classification on the Hypogonadotropic hypogonadism panel and the Hypogonadotropic hypogonadism (GMS) panel (R148), indicating strong evidence supporting its role in these conditions. It also appears on the Pituitary hormone deficiency panel (R159) with green status. This inclusion reflects the gene's recognised clinical utility in diagnosing patients presenting with delayed puberty, absent sexual development, or unexplained infertility where hypogonadotropic hypogonadism is suspected.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the difference between hypogonadotropic and hypergonadotropic hypogonadism?
Hypogonadotropic hypogonadism results from insufficient signalling from the brain to the gonads, leading to low levels of both sex hormones and the pituitary hormones LH and FSH. Hypergonadotropic hypogonadism occurs when the gonads themselves fail to respond to normal or elevated LH and FSH levels, such as in primary ovarian insufficiency or testicular failure. Blood tests measuring these hormone levels help distinguish between the two categories.
Can GNRHR-related hypogonadism be treated?
Hormone replacement therapy can effectively address many symptoms of GNRHR-related hypogonadism, supporting development of secondary sexual characteristics and maintaining bone health. For individuals seeking fertility, pulsatile GnRH therapy or gonadotropin injections can sometimes stimulate the gonads to produce gametes. Treatment approaches are individualised based on the person's age, symptoms, and reproductive goals, and should be discussed with an endocrinologist.
How is isolated hypogonadotropic hypogonadism diagnosed?
Diagnosis typically involves blood tests showing low sex hormones (testosterone or oestrogen) alongside low or inappropriately normal LH and FSH levels, which distinguishes it from primary gonadal failure. Imaging studies may assess pituitary anatomy, and smell testing can identify associated anosmia (loss of smell), which suggests Kallmann syndrome. Genetic testing can identify pathogenic variants in GNRHR and related genes, confirming the diagnosis and informing family planning.